Erythropoietic Protoporphyria - Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
Erythropoietic Protoporphyria
Overview
'Erythropoietic Protoporphyria
Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Erythropoietic Protoporphyria
Market. A Detailed Picture Of The Erythropoietic Protoporphyria
Pipeline Landscape Is Provided, Which Includes The Disease Overview And Erythropoietic Protoporphyria
Treatment Guidelines.
The Assessment Part Of The Report Embraces In-Depth Erythropoietic Protoporphyria
Commercial Assessment And Clinical Assessment Of The Erythropoietic Protoporphyria
Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.
In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Erythropoietic Protoporphyria
Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
Erythropoietic Protoporphyria
Of Pipeline Development Activities
The Report Provides Insights Into:
Analytical Perspective By DelveInsight
This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.
The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.
SCOPE OF THE REPORT
Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
REPORT HIGHLIGHTS
Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Erythropoietic Protoporphyria
Market Size In The Coming Years.
KEY QUESTIONS
?
Erythropoietic Protoporphyria
Overview
'Erythropoietic Protoporphyria
Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Erythropoietic Protoporphyria
Market. A Detailed Picture Of The Erythropoietic Protoporphyria
Pipeline Landscape Is Provided, Which Includes The Disease Overview And Erythropoietic Protoporphyria
Treatment Guidelines.
The Assessment Part Of The Report Embraces In-Depth Erythropoietic Protoporphyria
Commercial Assessment And Clinical Assessment Of The Erythropoietic Protoporphyria
Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.
In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Erythropoietic Protoporphyria
Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
Erythropoietic Protoporphyria
Of Pipeline Development Activities
The Report Provides Insights Into:
- All Of The Companies That Are Developing Therapies For The Treatment Of Erythropoietic Protoporphyria
- Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Erythropoietic Protoporphyria
- Erythropoietic Protoporphyria
- Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.
- Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Erythropoietic Protoporphyria
- The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.
Analytical Perspective By DelveInsight
- In-Depth Erythropoietic Protoporphyria
This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.
- Erythropoietic Protoporphyria
The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.
SCOPE OF THE REPORT
- The Erythropoietic Protoporphyria
Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
- It Comprises Of Detailed Profiles Of Erythropoietic Protoporphyria
- Detailed Erythropoietic Protoporphyria
- Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Erythropoietic Protoporphyria
REPORT HIGHLIGHTS
- A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Erythropoietic Protoporphyria
- In The Coming Years, The Erythropoietic Protoporphyria
- The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Erythropoietic Protoporphyria
- A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Erythropoietic Protoporphyria
Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Erythropoietic Protoporphyria
Market Size In The Coming Years.
- Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Erythropoietic Protoporphyria
KEY QUESTIONS
- What Are The Current Options For Erythropoietic Protoporphyria
- How Many Companies Are Developing Therapies For The Treatment Of Erythropoietic Protoporphyria
- What Are The Principal Therapies Developed By These Companies In The Industry?
- How Many Therapies Are Developed By Each Company For The Treatment Of Erythropoietic Protoporphyria
- How Many Erythropoietic Protoporphyria
?
- Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?
- What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Erythropoietic Protoporphyria
- Which Are The Dormant And Discontinued Products And The Reasons For The Same?
- What Is The Unmet Need For Current Therapies For The Treatment Of Erythropoietic Protoporphyria
- What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Erythropoietic Protoporphyria
- What Are The Clinical Studies Going On For Erythropoietic Protoporphyria
- What Are The Results Of The Clinical Studies And Their Safety And Efficacy?
- What Are The Key Designations That Have Been Granted For The Emerging Therapies For Erythropoietic Protoporphyria
- How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Erythropoietic Protoporphyria
1. REPORT INTRODUCTION
2. ERYTHROPOIETIC PROTOPORPHYRIA
2.1. Overview
2.2. History
2.3. Erythropoietic Protoporphyria
Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Erythropoietic Protoporphyria
Diagnosis
2.6.1. Diagnostic Guidelines
3. ERYTHROPOIETIC PROTOPORPHYRIA
Current Treatment Patterns
3.1. Erythropoietic Protoporphyria
Treatment Guidelines
4. ERYTHROPOIETIC PROTOPORPHYRIA
- DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Erythropoietic Protoporphyria
companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Erythropoietic Protoporphyria
Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Erythropoietic Protoporphyria
Acquisition Analysis
5. THERAPEUTIC ASSESSMENT
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. ERYTHROPOIETIC PROTOPORPHYRIA
Late Stage Products (Phase-III)
7. ERYTHROPOIETIC PROTOPORPHYRIA
Mid Stage Products (Phase-II)
8. EARLY STAGE PRODUCTS (PHASE-I)
9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
10. INACTIVE PRODUCTS
11. DORMANT PRODUCTS
12. ERYTHROPOIETIC PROTOPORPHYRIA
Discontinued Products
13. ERYTHROPOIETIC PROTOPORPHYRIA
Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. ERYTHROPOIETIC PROTOPORPHYRIA
Key Companies
15. ERYTHROPOIETIC PROTOPORPHYRIA
Key Products
16. DORMANT AND DISCONTINUED PRODUCTS
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. ERYTHROPOIETIC PROTOPORPHYRIA
Unmet Needs
18. ERYTHROPOIETIC PROTOPORPHYRIA
Future Perspectives
19. ERYTHROPOIETIC PROTOPORPHYRIA
Analyst Review
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Secondary Research
21.2. Expert Panel Validation
2. ERYTHROPOIETIC PROTOPORPHYRIA
2.1. Overview
2.2. History
2.3. Erythropoietic Protoporphyria
Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Erythropoietic Protoporphyria
Diagnosis
2.6.1. Diagnostic Guidelines
3. ERYTHROPOIETIC PROTOPORPHYRIA
Current Treatment Patterns
3.1. Erythropoietic Protoporphyria
Treatment Guidelines
4. ERYTHROPOIETIC PROTOPORPHYRIA
- DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Erythropoietic Protoporphyria
companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Erythropoietic Protoporphyria
Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Erythropoietic Protoporphyria
Acquisition Analysis
5. THERAPEUTIC ASSESSMENT
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. ERYTHROPOIETIC PROTOPORPHYRIA
Late Stage Products (Phase-III)
7. ERYTHROPOIETIC PROTOPORPHYRIA
Mid Stage Products (Phase-II)
8. EARLY STAGE PRODUCTS (PHASE-I)
9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
10. INACTIVE PRODUCTS
11. DORMANT PRODUCTS
12. ERYTHROPOIETIC PROTOPORPHYRIA
Discontinued Products
13. ERYTHROPOIETIC PROTOPORPHYRIA
Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. ERYTHROPOIETIC PROTOPORPHYRIA
Key Companies
15. ERYTHROPOIETIC PROTOPORPHYRIA
Key Products
16. DORMANT AND DISCONTINUED PRODUCTS
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. ERYTHROPOIETIC PROTOPORPHYRIA
Unmet Needs
18. ERYTHROPOIETIC PROTOPORPHYRIA
Future Perspectives
19. ERYTHROPOIETIC PROTOPORPHYRIA
Analyst Review
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Secondary Research
21.2. Expert Panel Validation
LIST OF TABLES
Table 1: Erythropoietic Protoporphyria
Diagnostic Guidelines
Table 2: Erythropoietic Protoporphyria
Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Erythropoietic Protoporphyria
Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Erythropoietic Protoporphyria
Late Stage Products (Phase-III)
Table 18: Erythropoietic Protoporphyria
Mid Stage Products (Phase-II)
Table 19: Erythropoietic Protoporphyria
Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
Table 1: Erythropoietic Protoporphyria
Diagnostic Guidelines
Table 2: Erythropoietic Protoporphyria
Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Erythropoietic Protoporphyria
Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Erythropoietic Protoporphyria
Late Stage Products (Phase-III)
Table 18: Erythropoietic Protoporphyria
Mid Stage Products (Phase-II)
Table 19: Erythropoietic Protoporphyria
Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
LIST OF FIGURES
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Erythropoietic Protoporphyria
companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Erythropoietic Protoporphyria
Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Erythropoietic Protoporphyria
companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Erythropoietic Protoporphyria
Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs